Pharmaceuticals, Biotechnology
British-Swedish multinational pharmaceutical company (LSE: AZN; NASDAQ: AZN). Focus areas: oncology, cardiovascular + renal + metabolic, respiratory, vaccines + immune therapies. $45bn revenue 2023. 89,000+ employees. AstraZeneca Thailand manages COVID-19 vaccine supply + innovative-medicines portfolio.
Composite score across 5 categories MNCs operating in Thailand can demonstrate.
How this is computed: a weighted average of 5 sub-scores. Higher weight on signals an MNC has agency over (Thailand venue depth, international disclosure framework adoption, DEI policy explicitness) and lower weight on audit / scale signals that depend on company size.
How AstraZeneca plcis showing up for Thailand's LGBTQ+ community
Inclusion Dividend
Not yet enrolled
Creator partners
0
verified Thai KOLs
Audit history
No audit yet
Thailand presence
Single market presence
PrideShow LGBTQ+ ESG score (global) — Thailand-specific signals are above
86
Platinum · A+
LGBTQ+ Policy
100
Supply Chain
75
Community
70
Reporting
100
Stonewall Top 100 Employers UK — multi-year top-10 ranking
2023 Sustainability Report — GRI / TCFD / CDP / SASB aligned
CDP Climate A-List (multi-year)
DJSI World + Europe + FTSE4Good Index constituent
Bloomberg Gender-Equality Index constituent
Axess — LGBTQ+ ERG with 30+ country chapters
Young Health Programme — adolescent mental health + addiction prevention
Signatory to UN Global Compact + SBTi net-zero
Ambition Zero Carbon — operations carbon-neutral by 2025
Access to Medicines Index top-5
Transgender-inclusive healthcare + Disability Confident Leader (UK)
Reach AstraZeneca plc's Thailand and APAC teams through PrideShow. Whether you're an NGO with a partnership idea, an SME on the supplier path, or a fellow MNC exploring co-activation — start the conversation here.
Is this your company?
Claim the listing to manage your Thailand inclusion evidence, respond to inbound enquiries, and connect with NGO and creator partners. Or sponsor PrideShow 2026 directly.
